Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yasumasa Yoshiki"'
Autor:
Yasushi Yatabe, MD, PhD, Yasumasa Yoshiki, MPH, Koichi Matsumura, PhD, Kanae Togo, MSc, Hironori Kikkawa, PhD, Laura Iadeluca, PhD, MPH, Benjamin Li, PhD, Kazuto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136- (2021)
Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Informatio
Externí odkaz:
https://doaj.org/article/32ccbf8e9d9347f381ea1ab2194febed
Autor:
Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio
Publikováno v:
Cancer Science.
Autor:
L. Iadeluca, N. Shiraiwa, Yasushi Yatabe, Birol Emir, Makoto Nishio, Yasumasa Yoshiki, Kazumi Nishino, Takashi Takahashi, Kazuto Nishio
Publikováno v:
Journal of Thoracic Oncology. 16:S1151-S1152
Autor:
Kazuto Nishio, Yasushi Yatabe, Benjamin Li, L. Iadeluca, Hironori Kikkawa, Koichi Matsumura, Yasumasa Yoshiki, Kanae Togo
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136-(2021)
Introduction Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Information
Autor:
Kazumi Nishino, L. Iadeluca, Yasumasa Yoshiki, Birol Emir, Kazuto Nishio, Kanae Togo, Toshiaki Takahashi, Yasushi Yatabe, Makoto Nishio
Publikováno v:
Annals of Oncology. 32:S300
Autor:
Kanae Togo, Birol Emir, Koichi Matsumura, L. Iadeluca, Hironori Kikkawa, Elizabeth T. Masters, L. Becnel, Yasushi Yatabe, R. Wiltshire, Kazuto Nishio, Yasumasa Yoshiki
Publikováno v:
Journal of Thoracic Oncology. 16:S162